Highest-materiality recent filing
Astrana Health CAO Glenn Sobotka to retire; John Vong to succeed as principal accounting officer
Glenn Sobotka will retire as Chief Accounting Officer effective August 7, 2026; no disagreement with company.
Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing shares reserved by 1,000,000 to a total of 5,100,000 shares.
Astrana Health CMO Dinesh Kumar resigns effective June 1, 2026
Dinesh Kumar, M.D., Chief Medical Officer, notified resignation on May 7, 2026.
Astrana Health updates investor presentation with Q1 2026 metrics and FY2026 outlook
Presentation includes G&A efficiency chart with data for FY2023-FY2026E and Q1 2025/Q1 2026.
Astrana Health Q1 revenue up 56% to $965M; adjusted EBITDA up 82% to $66.3M
Total revenue $965.1M, up 56% YoY; Care Partners revenue $909.7M, up 51%.
Astrana Health files interim financials of acquired Prospect entities; pro forma included
Acquired Business (PHPH & RI Market) nine-month net loss $38.7M vs $43.7M year-ago; total net revenue $961.8M (+9.6% YoY).
Astrana Health expects material weakness in internal controls; 10-K filing by extension deadline
Updated investor presentation furnished; no specific new financial or strategic details.
FY2025 total revenue $3.18B (+56% YoY); at high end of guidance; Care Partners revenue $3.02B (+55%).
Astrana Health furnishes updated investor presentation; no material new information disclosed
Corporate presentation updated effective January 12, 2026, for use at conferences and meetings.
Astrana Health Q3 revenue $956M (+100% YoY); adjusted EBITDA $68.5M; closes Prospect Health
Total revenue $956.0M, up 100% YoY; Care Partners revenue $897.7M, up 97%.
Acquired PHP Holdings reports FY2024 net loss of $78.7M on $1.19B revenue; high leverage
PHP Holdings net loss $78.7M in FY2024 vs net income $30.5M in FY2023, driven by $138.3M interest expense.
Astrana Health Q2 revenue $654.8M, +35% YoY; adjusted EBITDA $48.1M, guidance reiterated
Total revenue $654.8M, up 35% from $486.3M; adjusted EBITDA $48.1M, both at higher end of guidance.
Astrana closes Prospect Health acquisition for $708M, updates FY 2025 guidance
Purchase price reduced from $745M to $708M; closed July 1, 2025.
Stockholders approved increase of 2,000,000 shares under 2024 Equity Incentive Plan (total 4,100,000 shares reserved).
Astrana Health updates corporate investor presentation; details not provided
Company furnished updated corporate presentation as Exhibit 99.1 for use at conferences and meetings.
Astrana Health furnishes updated corporate presentation; no material new data
Company posted an updated investor presentation dated May 2025 for conference use.
Astrana Health Q1 revenue up 53% to $620M; net income down to $6.7M
Total revenue $620.4M (+53% YoY); Care Partners revenue $601M (+57%).
Astrana Health appoints Glenn W. Sobotka as Chief Accounting Officer (CAO), effective March 26, 2025
John Vong transitions to a new role and ceases as principal accounting officer on the same date.
Astrana Health files 8-K/A correcting preliminary FY2024 balance sheet; goodwill down $18.4M
Goodwill decreased by $18.4M (from $437.7M to $419.3M) due to Q4 acquisition adjustments.
Astrana Health updates corporate presentation; no material new information disclosed
Updated presentation filed as Exhibit 99.1 for use in conference and investor meetings.
Astrana Health updates corporate presentation; no specific details provided in filing
Filed under Item 7.01; presentation attached as Exhibit 99.1 is not reproduced in the filing text.
Astrana Health enters $1.295B credit facility; $745M delayed draw for Prospect acquisition
Five-year $300M revolver, $250M term A loan, and $745M delayed draw term loan.
Astrana Health FY2024 revenue up 47% to $2.03B, net income down 29% to $43.1M
Total revenue $2,034.5M (+47% YoY); Care Partners revenue $1,949.0M (+52%).
Astrana Health repurchases 300,000 shares from affiliate APC for $10.6M
Repurchased 300,000 shares at $35.17 each, aggregate $10.55M, based on Jan 17 closing price.
Astrana Health: Prospect Medical Ch. 11 filing excludes acquisition assets; deal unaffected
Prospect Medical Holdings filed for Chapter 11 bankruptcy on January 11, 2025, in the Northern District of Texas.
Astrana Health files 8-K furnishing investor presentation for upcoming conferences
Astrana Health (ASTH) filed an 8-K on Nov 14, 2024, disclosing a slide presentation (Exhibit 99.1) for use at upcoming conferences.
Astrana Health grants one-time equity awards to Chairman, CEO, COO/CFO, and CMO to boost retention
Kenneth Sim: 200,000 restricted shares (133,333 performance, 66,667 time-based).
Astrana Health to acquire Prospect Health for $745M; adds ~610k members
Purchase price of $745 million plus assumption of certain liabilities; expected close mid-2025 subject to regulatory approval.
Astrana Health to acquire hospital, health plan & ACO for $745M; arranges $1.195B financing
Acquires equity of Prospect Health Plan, Alta Newport Hospital (Foothill Regional), and Prospect ACO Rhode Island for $745M.
Astrana Health Q3 revenue up 37% to $478.7M; net income down 27% to $16.1M
Q3 net income $16.1M (-27% YoY); diluted EPS $0.33 (-30%); adjusted EBITDA $45.2M (-13%).
Astrana Health completes acquisition of Collaborative Health Systems and affiliates
Closed acquisition of Collaborative Health Systems, LLC, Golden Triangle Physician Alliance, and Heritage Physician Networks on Oct 4, 2024.
Astrana Health furnishes investor presentation for conferences; no specific financial data disclosed
Slides for upcoming conference presentations provided as Exhibit 99.1.
Astrana Health Q2 revenue up 40% to $486.3M, EPS $0.40; acquires CHS from Centene
Q2 revenue $486.3M (+40% YoY), net income $19.2M (+46%), diluted EPS $0.40 (+43%), adjusted EBITDA $47.9M (+34%).
Purchase price $37.5M plus earnout up to $21.5M for CHS, GTPA, and HPN.
Astrana registers Earn-Out Shares for resale; no proceeds to company
Filed prospectus supplement on July 15, 2024 for resale of Earn-Out Shares.
Astrana Health files certificate amendment to exculpate officers under Delaware law
Amendment to restated certificate of incorporation approved by stockholders on June 12, 2024.
Shareholders approve 2024 Equity Incentive Plan adding 2.1M shares; all director nominees elected
All nine director nominees elected at June 12 annual meeting; quorum of 75.6%.
Astrana Health amends credit agreement to allow letters of credit extending beyond maturity date
Fourth Amendment to Amended and Restated Credit Agreement dated May 20, 2024, with Truist Bank as agent.
Astrana Health furnishes investor presentation; no material new details evident
Form 8-K filed under Item 7.01 with an investor presentation as Exhibit 99.1.
Astrana Q1 revenue $404.4M (+20% YoY), net income $14.8M (+13%), EPS $0.31
Total revenue $404.4M (+20% YoY); net income attributable $14.8M (+13%); diluted EPS $0.31 (+11%).
Dr. Albert Young transitions from CAO to SVP of Health Affairs at Astrana Health
Dr. Albert Young transitioned from CAO to SVP of Health Affairs effective April 23, 2024.
Astrana Health eliminates Series A and B preferred stock designations from charter
Filed Certificate of Elimination removing Series A and Series B Convertible Preferred Stock designations.
Astrana Health amends CEO & COO/CFO employment pacts, grants $13M in equity
CEO Brandon Sim new base salary $850k, target bonus 125%; CFO Chandan Basho base $600k, target bonus 80%.
Astrana Health completes acquisitions of AHMS and 25% of I Health; purchase agreements amended
Completed second closing on March 31, 2024, acquiring all partnership interests of Advanced Health Management Systems (AHMS).
Astrana Health issues FY2024 revenue $1.65-1.85B, Adj. EBITDA $165-185M
FY2023 rev $1.39B, Adj. EBITDA $146.6M, diluted EPS $1.29.
Astrana Health amends bylaws for universal proxy; sets annual meeting June 12
Bylaws effective Feb 28, 2024, add universal proxy procedural mechanics per SEC Rule 14a-19.
Astrana Health FY2023 revenue $1.39B (+21%), net income $60.7M (+34%), EPS $1.29 (+30%)
Total revenue $1,386.7M, up 21% from $1,144.2M in 2022.
Apollo Medical Holdings renamed Astrana Health; ticker now ASTH
Name change from Apollo Medical Holdings, Inc. to Astrana Health, Inc., effective February 26, 2024.
Apollo Medical Holdings completes first closing of CFC asset acquisition; amends purchase agreement
First closing for CFC assets completed Jan 31, 2024; second closing for AHMS expected Q1 2024.
Apollo Medical Holdings to rename to Astrana Health; ticker changes to ASTH on Feb 26
Name change from Apollo Medical Holdings, Inc. to Astrana Health, Inc. effective Feb 26, 2024.
On May 7, 2026, Dinesh Kumar, M.D., the Chief Medical Officer of Astrana Health, Inc. (the “Company”), notified the Company of his intention to resign, effective as of June 1, 2026.
On March 26, 2025, Astrana Health, Inc. (the “Company”) appointed Glenn W. Sobotka as the Company’s Chief Accounting Officer and principal accounting officer, effective March 26, 2025
John Vong, the Company’s current Chief Accounting Officer and principal accounting officer, will transition to a new role at the Company and will no longer serve as the principal accounting officer as of the Effective Date.
Effective April 23, 2024, Dr. Albert Young transitioned from his position as Chief Administrative Officer of Astrana Health, Inc. (the “Company”) to a new role as Senior Vice President of Health Affairs of the Company.
· Chandan Basho, previously Chief Financial Officer and Chief Strategy Officer, was appointed Chief Financial Officer and Chief Operating Officer.
· Thomas S. Lam, M.D., M.P.H., previously Co-Chief Executive Officer and President and a director, was appointed Vice Chairman of the Board;
· Brandon Sim, previously Co-Chief Executive Officer, was appointed Chief Executive Officer and President;
On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer.
On February 2, 2023, Michael Eng notified the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”) of his decision to resign as a member of the Board effective as of February 15, 2023.
On November 30, 2022, Apollo Medical Holdings, Inc. (together with its subsidiaries and affiliated entities, “Company”) appointed John Vong as the Company’s Chief Accounting Officer.
In connection with the appointment, Eric Chin will step down for personal reasons as Chief Financial Officer effective May 5, 2022.
On May 5, 2022, the Company appointed Chan Basho as the Company's Interim Chief Financial Officer, effective May 5, 2022.
Max materiality 0.85 · Median 0.50 · Most common event other_material